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Rare inherited anemias are a subset of anemias caused by a genetic defect along one of the several stages of erythropoiesis or in
different cellular components that affect red blood cell integrity, and thus its lifespan. Due to their low prevalence, several
complications on growth and development, and multi-organ system damage are not yet well defined. Moreover, during the last
decade there has been a lack of proper understanding of the impact of rare anemias on maternal and fetal outcomes. In addition,
there are no clear-cut guidelines outlining the pathophysiological trends and management options unique to this special population.
Here, we present on behalf of the European Hematology Association, evidence- and consensus-based guidelines, established by an
international group of experts in different fields, including hematologists, gynecologists, general practitioners, medical geneticists, and
experts in rare inherited anemias from various European countries for standardized and appropriate choice of therapeutic
interventions for the management of pregnancy in rare inherited anemias, including Diamond-Blackfan Anemia, Congenital
Dyserythropoietic Anemias, Thalassemia, Sickle Cell Disease, Enzyme deficiency and Red cell membrane disorders.ivision of Hematology and Oncology, Department of Internal Medicine,
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Recommendations for pregnancy in rare
anemias
Questions:
1. Why specific guidelines for pregnancy in RIAs? What
makes RIAs different from the most common con-
ditions of anemia in pregnancy? When does an RIA
deviate from the standard guidelines for anemia in
pregnancy?
Rare inherited anemias (RIA) are a subset of anemias
caused by amyriad of genetic defects in one of the stages
of red blood cell (RBC) cellular component formation
or erythropoiesis. The result of those defects is
detrimental to the RBC integrity, and thus its lifespan
or its production. Due to their rare prevalence, the full
spectrum of disease complications and multi-organ
system damage remains ill-defined. More importantly,
less is known about RIA’s impact on growth, develop-
ment, and long-term morbidity. The significant medical
advances made in the field of benign hematology have
resulted in near normalization of RIA’s patients’
longevity. Thus, the incidence of pregnancy among
affected patients is steadily increasing. A better
understanding of the impact of such rare anemias on
maternal and fetal outcomes and evidence-based
management guidelines is of paramount importance.
2. When should a pregnancy in an inherited anemia be
considered at risk?
Pregnancy in RIA should always be considered high
risk regardless of underlying risk factors. All available
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complications seen throughout pregnancy in individu-
als with RIA. These complications vary depending on
the type of anemia, its severity in addition to the
predisposing pathophysiology of the disease.
3. What should be addressed?
The approach that should be taken once a woman
with RIA and her partner are planning a pregnancy
should be multidisciplinary with collaboration among
the hematologist, gynecologist and geneticist.
a. The hematologist: has a role in optimizing the
management of anemia, iron chelation, complica-
tions secondary to iron overload and anemia.
b. The gynecologist: has a role in addressing the risks of
pregnancy on the mother along with the risk during
delivery. He should monitor fetal complications such
as growth restriction, fetal distress or hydrops fetalis.
4. Should the genetic and clinical counseling be given
together?
The geneticist has a role prior and during pregnancy
onset by explain risk of pregnancy and risks of having
offspring with the disease mainly in particular genetic
disorders. This consultation must include also the
examination of the partner, searching for an inherited
red cell defects that could modify the expected
phenotype. Hence, genetic counselling should take place
whenever inherited formof anemia is suspected based on
the medical/family history of any of the partners.
5. When to consider prenatal diagnosis?
Prenatal workup should be initiated whenever
clinicians have a suspicion of an affected baby. This
should be considered as early as possible once
suspected. During pregnancy, close monitoring with
regular fetal ultrasound can orient the clinicians on
doing prenatal diagnosis.
Especially in the caseofdominant conditionorwhen the
partner is also affected with an inherited form of anemia.
6. Which tests are useful planning a pregnancy in RIA?
Maternal workup should be done prior to pregnancy
to decrease risks of complications:
 Evaluate iron status (using serum ferritin and
transferrin saturation) and ensure adequate manage-
ment of iron overload (if required liver and cardiac
iron assessment bymagnetic resonance imagingMRI)
 Assess cardiac status with echocardiography and
manage accordingly
 Check viral status (Hepatitis B, Hepatitis C and HIV)
and provide proper vaccination (Hepatitis B, Pneu-
mococcus, seasonal influenza)
 Evaluate folate stores (as this population is at risk of
folate deficiency) and offer preventive or curative
supplementation
7. Which tests are useful during the pregnancy?
 Monitor hematological parameters, cardiac, hepatic,
renal, endocrine (glucose tolerance) and thyroid
functions
 Monthly Doppler ultrasound starting week 20 of
gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
 Splenectomized patient should be considered for
aspirin therapy2
 NTDT should be on a prophylactic dose of anti-
coagulation in peripartum
 Regular folic acid supplementation 800 to 1000mg
daily is recommended in all mothers to prevent
superimposed megaloblastic anemia
 Delivery modality should be discussed between the
patient and her gynecologist viewing the risks and
complications that are possible to take place
 Optimize patient for vaginal vs cesarean section (C/S
for high risk and poorly controlled patients)
8. Special advice for the post-partum in RIAs?
Close monitoring should continue post-partum for at
least first month. Anemia should be monitored, and
iron chelation might need to be resumed earlier in cases
with highly iron overloaded. Vitamin supplementation
such as Calcium and Vitamin D is highly recommended.
9. May a pregnancy help to suspect a diagnosis of RIA?
In rare situations, such in subclinical RIA women
may develop severe anemias during pregnancy and
become symptomatic putting her fetus at risk. Hence, in
this case, clinicians should opt to manage these
pregnancies same as the high-risk RIA pregnancies.
In rare cases, pregnant women may have enhancement
of their symptoms due to pregnancy which will cause
delay in diagnosis and proper management of RIA.
10. When should iron be considered in RIAs during
pregnancy?
Iron supplementation is not recommended in RIA
pregnancies, unless there is documentation of true iron
deficiency through laboratory iron testing. On the other
hand, many patients have iron overload due to multiple
blood transfusions and require iron chelation.
11. When should transfusion be considered in RIAs during
pregnancy?
Maternal anemia, defined as Hb < 11.6g/dL during
the first trimester of pregnancy, or Hb < 9.7-9.5 g/dL
during the second and third trimester, affects 7.5% to
8.6% of the population and is objectively proven to be
an independent risk factor for maternal and fetal
morbidity during pregnancy and deliver. Gestational
anemia is objectively associated with higher rates of
abnormal placentation, low birth weight, and preterm
delivery. However, it is preferable that the decision
of transfusion be based on maternal symptoms of
anemia or risk of fetal distress, rather than hemoglobin
level.
12. Is there a role for erythropoietin (EPO) or other therapies?
The role of recombinant human EPO is controversial.
Minimal data is available to show benefit with their use.
However, some case reports have demonstrated its
affectivity mainly in patients with NTDT in whom allo-
immunization may complicate the availability of
further safe transfusions.
13. When to suspect an RIA in an asymptomatic patient
with mild anemia?
RIA should be suspected whenever anemia is
associated with clinical features that fulfill the specific
characteristics of each disease: Diamond-Blackfan
anemia, congenital dyserythropoietic anemias, thalas-
semia, sickle cell disease, pyruvate kinase deficiency, red
cell membrane disorders.
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(2020) 4:4 www.hemaspherejournal.comIntroductiona myriad of genetic defects affecting erythropoiesis stages or one
Rare inherited anemias (RIA) are a subset of anemias caused by
red blood cell (RBC) component (Diamond-Blackfan anemia,
congenital dyserythropoietic anemias, thalassemia, sickle cell
disease, enzyme deficiencies, red cell membrane disorders).1 The
result of those defects is detrimental to the RBC integrity, and
thus its lifespan.2 Due to their rare prevalence, the full spectrum
of disease complications and multi-organ system damage remains
not well defined. More importantly, less is known about RIAs’
impact on growth, development, and long-term morbidity. The
significant medical advances made in the field of benign
hematology have resulted in near normalization of RIA patients’
longevity. Thus, the incidence of pregnancy among affected
patients is steadily increasing.3,4 A better understanding of the
impact of such rare anemias on maternal and fetal outcomes and
evidence-based management guidelines is of paramount impor-
tance; however, high-quality evidence is lacking upon which to
base guidelines. Nevertheless, recommendations are needed to
help guide clinicians looking after these patients at this vulnerable
time in their life.
Maternal anemia is defined as Hb < 11g/dL during the first
trimester of pregnancy, as Hb <10.5g/dL during the second
trimester and as Hb < 11 g/dL during the third trimester.5–7 It
affects large groups of women worldwide and can range from
16.5% to 41.5% of pregnant women in High-income countries
and Low-middle income countries, respectively.8 This number of
maternal anemia represents 7.5% to 8.6% of the world
population and is proven to be an independent risk factor for
maternal and fetal morbidity during pregnancy and delivery.8–10
Gestational anemia has been shown to be associated with higher
rates of abnormal placentation, low birth weight, and preterm
delivery.11,12 In these recommendations, we analyzed the effects
of RIAs on pregnancy outcomes based on available literature.
This is an overview of the pathophysiology, followed by
pregnancy-specific outcomes and management outlines for the
most relevant forms of RIAs.
The aim of this paper was to develop European recommen-
dations for the clinical management of pregnancies in patients
with inherited anemias on behalf of the European Hematology
Association (EHA). After a thorough review of the literature by
experts in relevant fields, including hematologists, gynecologists,
general practitioners, medical geneticists, and experts in inherited
anemias from various European countries, a Delphi-like
consensus process was used to produce statements and practical
algorithms for the management of pregnancy in rare inherited
anemias, including Diamond-Blackfan anemia, congenital dyser-
ythropoietic anemias (CDAs), thalassemia, sickle cell disease,
enzyme deficiency and red cell membrane disorders.Methods
Our recommendations are based on a systematic literature
search. All articles on pregnancy and inherited anemias were
identified by a PubMed, Online Mendelian Inheritance in Man,
and Textbook search, including all the additional relevant
references cited in the articles found. The key search terms
“inherited anemias” and “chronic anemias”were used alone and
in combination with the term “pregnancy”. The examined period
was from June 2019 to January 2020. We used the same search
method as in our previously published systematic review.13 All3
reviewed articles and abstracts were restricted to those published
in the English language.
The steering committee and expert panel included 20 members
who have been selected for their recognized expertise in research
and clinical practice in RIA, with a wide geographical
representation in order to provide an international perspective.
EHA verified the absence of relevant competing conflict of
interests of the authors and supervised the project in regard to
compliance to, and consistency with, the methodology adopted
by its Committee on Guidelines. EHA provided the organiza-
tional and logistic assistance and funding for the necessary face-
to-face meetings or teleconferences. With this background, a
series of questions regarding pregnancy in inherited anemias were
formulated and the relative recommendations were produced. An
agreement was obtained using a Delphi-like approach. Multiple
rounds of questionnaires have been generated by a steering
committee and a final questionnaire has been sent to a panel of
experts. The responses by this expert panel have been aggregated
and shared with the group after each round. The experts adjusted
their answers in subsequent rounds; thus, the final response has
been reached through consensus.Practical recommendations for all rare
anemias
The pregnancy in women affected by rare anemias must be
planned ahead of time with close monitoring by an experienced
multidisciplinary team. The immune system of pregnant women
with rare anemias is often compromised due to the elevated
estrogen levels of pregnancy, the variable state of iron overload,
and the absence of a spleen in some cases.14 Therefore, all women
with a rare anemia should be screened for the human
immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, and
rubella. Of note, genetic counseling should be offered to all RIAs
women, preferably before any pregnancies. Therapy should be
recommended for HIV positive or Hepatitis C positive women
before pregnancy.15 Treatment of the hepatitis C virus with either
interferon or ribavirin should be discontinued six months prior to
pregnancy. Patients who have been splenectomized should be on
penicillin prophylaxis and be up to date with all of their vaccines,
in particular the 5-yearly pneumococcal booster.16 Moreover,
endocrinopathies including hypogonadism which is secondary to
iron overload should be expected whenever women with RIA
present for pre-pregnancy workup. Lastly, genetic counseling
with both parents should be offered along with antenatal testing
when medical or family history is suggestive. Table 1 summarizes
the practical recommendations that should be taken into
consideration before conception, during pregnancy and delivery,
and postpartum.Diamond-Blackfan anemia
Diamond-Blackfan anemia (DBA) is a rare form of congenital
pure red-cell aplasia caused by a genetic disorder in ribosome
synthesis that causes pro-apoptotic hematopoiesis leading to
bone marrow failure. Central to the pathophysiology of DBA is
erythropoiesis failure, which is due to an intrinsic progenitor
defect leading to insensitivity to erythropoietin and to other
erythroid factors.17 Phenotypically, the disease manifests as a
variable combination of severe anemia, congenital malforma-
tions, growth retardation, and cancer predisposition.18,19
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Table 1
Summary of the Practical Recommendations for all Rare Anemias
Throughout Pregnancy.
Pre-Conception:
1- Evaluate iron overload status and ensure adequate management of iron
overload.26,48
2- Assess cardiac status and manage accordingly.14,56
3- Check viral status (Hepatitis B, Hepatitis C and HIV) and provide proper
vaccination (Hepatitis B, Pneumovax, seasonal influenza).
4- Offer genetic counseling if not previously done (preferably to be done before
pregnancy or at any time during pregnancy).
5- Prevention of folate deficiency (frequent in this population of patients) before 1st
trim by careful oral supplementation (risk of neural tube defect).
6- Perform a multidisciplinary clinical evaluation and a roundtable discussion among
physicians and patient regarding the potential risks.
7- Evaluate the severity of anemia and plan a treatment strategy according to the
patient clinical status.
During Pregnancy:
1- Monitor cardiac, hepatic and thyroid function.26,56
2- Blood transfusions should be evaluated according to need
3- Stop iron chelation at least till 3rd trimester.
4- Serial ultrasound to monitor growth restriction, fetal distress or hydrops
fetalis.48,132
5- Some women with rare anemias especially NTDT patients should be on a
prophylactic dose of anticoagulation in peripartum and postpartum.
6- Splenectomized patient should be considered for aspirin therapy.26
7- Screen for gestational diabetes.
8- Regular folic acid supplementation is recommended in all mothers to prevent
superimposed megaloblastic anemia.
During Labor and Delivery:
1- Optimize patient for vaginal Vs. Cesarean Delivery (Cesarean Delivery for high risk
and poorly controlled patients)48,132
2- Epidural anesthesia with Cesarean Delivery.133
Postpartum:
1- Restart Iron chelation if ferritin is elevated.14,48
2- Supplement with calcium and Vitamin D
3- Monitor Hb level.
Taher et al Recommendations for Pregnancy in Rare Inherited AnemiasThe most commonly seen mutations are in the gene encoding
the Ribosomal Protein S19 (RPS19).20,21 The mode of inheri-
tance is heterogeneous and mostly sporadic, in around 75% of
the time. However, familial DBA exist and can be as autosomal
dominant with incomplete penetrance or rarely as X-linked
transmission. Approximately 55% to 75% of affected patients
have a de novo variant.20 The common presentation of DBA
includes macrocytic normochromic anemia and reticulocytope-
nia with no other affected cell lineages. Usually, it presents early
in life. Bone marrow inspection shows normal cellularity with a
paucity of erythroid precursors.22
Although corticosteroid therapy is the first-line treatment in
DBA, their mode of action is still unknown. More than 80% of
DBA patients will respond initially to steroid treatment.
However, some will become refractory to the first-line treatment
and will require chronic transfusion therapy.23 Hematopoietic
stem cell transplantation has recently proven to be a curative
treatment for anemia in DBA patients.24 Forty percent of affected
individuals are corticosteroids dependent, 40% transfusion-
dependent, and 20% experience remission.25,26Pregnancy-specific complications
Advances in the treatment of DBA have improved the
demographics of affected individuals. DBA is no longer limited4
to children but has shifted to becoming a chronic disorder with an
increasing incidence among adults.27 Women are now able to
reach childbearing age with limited morbidity and higher quality
of life, as well as a positive reproductive potential. On the other
hand, maternal, fetal, and neonatal complications are numer-
ous.28 Due to the sparsity of available data, we still lack a clear
description of risk factors and outcomes. Several case reports of
DBA in pregnancy were summarized in one review article.29
Twenty-five women affected by DBA, with a total of 29
pregnancies were included. Overall, 40% of the pregnancies
required multiple transfusions, and 30% required steroids. All
steroid-treated patients were also transfused. They reported an
increased risk of cesarean section (C/S) (25%), low birth weight
(21%), and premature delivery of offspring with and without
DBA.29
Another large prospective study of 64 pregnancies in 24 DBA-
affected women reported adverse outcomes in 66% of pregnan-
cies. Complications included worsening of anemia, increased
transfusion requirements, resistance to corticosteroid, higher
rates of intrauterine growth retardation, fetal malformation,
preterm delivery, fetal death in utero, and miscarriage.30 Around
41% of the liveborn offspring were affected by DBA. Congenital
malformations were noted in 12.5% of all pregnancies and were
independent of the DBA status of the child.30 It is essential to
stress that the direct causes of these complications are not clear—
whether from DBA itself, anemia, iron overload, or even steroid
use.
An interesting case report describes three pregnancy out-
comes of a woman affected by DBA.31 The patient’s first
pregnancy at the age of 33 endedwith a stillbirth at week 30. An
interesting observation made by the author is that her
hematocrit (Hct) spontaneously increased after week 25 of
gestation. During the patient’s second pregnancy, she received
transfusions during the first trimester to keep her Hct > 25%.
After week 19 of gestation, her Hct spontaneously increased.
She delivered a healthy newborn at 36 weeks gestational age.
Postpartum, her hematocrit level remained elevated during the
23 months of breastfeeding. Her third pregnancy was identical
to the second onewith spontaneous remission during pregnancy
and breastfeeding, followed by relapse.32 The authors hypoth-
esized that the leading cause of this peripartum remission was
the high level of prolactin. Previous studies and case reports
have shown the role of prolactin in erythropoiesis. Supra-
physiologic prolactin levels during pregnancy and breastfeed-
ing may be the reason behind improved outcomes in DBA.
Additionally, patients treated with Metoclopramide, a prolac-
tin agonist, experienced significant improvement in their
anemia.31 The pregnancy outcomes of women affected by
DBA are summarized in Table 2.Management during pregnancy
Preconception consultations with maternal-fetal medicine,
medical geneticist, and hematology specialists are crucial for
DBA-affected women planning a pregnancy. The risk of
transmitting DBA to the offspring should be discussed. There
are no clear guidelines on the use of iron chelators in DBA
patients and in general, management of iron chelation therapy
during pregnancy remains controversial.33 However, recom-
mendations from other rare anemias, such as thalassemia, can be
taken into account. Hence, ideally iron chelation should be
optimized well ahead of conception since the use of most
chelators is not recommended during pregnancy. In cases of
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Table 2
Summary of the Pregnancy Outcomes of the Largest Published Case Series of DBA.
No. women No. Pregnancies No. babies Gestation (wk) Mean BW (Kg) No. with low BW No. C/S No. Spon abns
Alter et al29 25 29 28 38 (33–40) 2.621 6 7 1
Faivre et al30 36 64 34 25 (6–42) 2.769 4 – 24
Abkowitz et al31 1 3 2 36 – – – 1
Gansner et al134 4 8 2 38 (36–39) 2.58 1 – 6
Giri et al135 9 41 29 – – – 5 12
Total 75 145 95 30 (6–42) 2.6 11 12 44
BW = body weight at birth; C/S = cesarean section; DBA = Diamond-Blackfan anaemia; Spon abns = spontaneous abortions.
(2020) 4:4 www.hemaspherejournal.comsevere iron overload, however, iron chelation could be considered
during the last trimester with a preference for deferoxamine—
based on the data available in pregnant women with thalasse-
mia.34 Anemia should also be regularly corrected for optimal
fetal oxygenation, although there is no consensus on how
low hemoglobin levels can be tolerated. Moreover, blood
transfusion should be considered once hemoglobin level drops
below 10g/dL26; although the decision to transfuse should be
driven by the clinical presentation of the patient and fetal growth
status rather than maternal Hb per se. Aspirin 80 to 100mg daily
has shown to be beneficial in some cases since many of the
observed complications have similar presentations to placental
vasculopathy.30 Finally, utero-placental Doppler ultrasound
should be used to continuously monitor and screen for any
congenital abnormalities in the fetus or possible placental
vascular disorder.
Box 1: Summary of the Practical Recommendations
for DBA.Monitor Hb level and transfuse if symptomatic or fetal
growth distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Genetic counseling on risk of fetal attaint with DBA
Acetyl salicylic acid 80 to 100 mg once daily during
pregnancy
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Congenital dyserythropoietic anemias
Congenital dyserythropoietic anemias (CDAs) are a heteroge-
neous subset of hypo-productive anemias where the defect lies in
abnormal late-stage differentiation and proliferation of the
erythroid lineage.35 There are currently 6 types of CDA, which
are distinguished by a combination of bone marrowmorphology,
laboratory findings, characteristic physical presentations, and
well-identified causative genes. Common hallmarks of the
diseases are chronic hypo-regenerative anemia, relative retic-5
ulocytopenia, a hemolytic component, and iron overload.36
Cholelithiasis, splenomegaly, and secondary hemochromatosis
are complications found in the most common types—I and II.35
CDAs are rare inherited disorders, with 0.04 cases/million in
North Europe and 2.49 cases/million inMediterranean countries.
Allelic heterogeneity is found in the different types of CDA, and
the founder effect explains the appearance of specific mutations
within different geographical groups worldwide.37,38
The following criteria should generally be met to diagnose a
suspected case of congenital dyserythropoietic anemia: 1.
evidence of anemia, jaundice, and splenomegaly; 2. evidence of
ineffective erythropoiesis; 3. occurrence of typical morphological
features of erythroblasts at bone marrow (BM) examination; and
4. exclusion of other congenital anemias that fulfill criteria 1 and
2, such as thalassemia syndromes and other inherited bone
marrow failure syndromes.39 Up to 20% of CDA patients can
present with congenital anomalies, particularly syndactyly in
hands or feet, absence of nails or supernumerary toes, and pigeon
chest deformity, among others.40,41 Proper use of genetic
confirmation, along with sensitive laboratory tools and BM
morphology findings, can aid in the differential diagnosis.38
Depending on the severity of the case, some patients may be
born with hydrops fetalis or require transfusions for survival
while others may remain asymptomatic even in adulthood,
requiring no intervention.38 Regular follow up with CBC, iron
balance parameters, and spleen/gallbladder evaluation is the
typical management, with RBC transfusions used as required.
Splenectomy has been helpful in transfusion dependent CDA II
cases only. Response to IFN-a therapy, with high variability, has
been documented with CDA I patients. Finally, BM transplanta-
tion has been efficacious in CDA,mostly in type I and II leading to
a curative state.38,42,43Pregnancy-specific complications
Knowledge about maternal and fetal pregnancy outcomes in
CDA is limited to case reports and a short review of a Bedouin
tribe with CDA type I.44 Historical data of CDA II, previously
coined HEMPAS (Hereditary Erythroblastic Multinuclearity
associated with a Positive Acidified Serum test) before proper
genetic classification, described 7 cases of affected pregnant
women whose deliveries were only complicated by the worsening
of their anemias. They required blood transfusion when their
condition became severe, but there were no adverse fetal
outcomes.45,46 The most extensive pregnancy outcome data
comes from 28 spontaneous pregnancies in six Bedouin women
with CDA I.12,47 Sixty-four percent of these pregnancies were
complicated: there was one first-trimester spontaneous abortion
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Taher et al Recommendations for Pregnancy in Rare Inherited Anemiasand one stillbirth; 42% had lower birth weights and 36% had
cesarean sections.48 A more recent case of a 26-year-old
primigravida woman with CDA I was reported, whereby she
suffered from pre-eclampsia and required C/S.47 When a North
Swedish family with CDA III was followed, common symptoms
of weakness, fatigue, and headache were reported to be
worsening during pregnancy. Five patients (20%) received blood
transfusions, 4 of them in late pregnancy or after delivery.49
Scarce data exist on the incidence of pregnancy in CDA women.
Some references consider that women with CDA who achieved a
complete pregnancy with minimal complications might have
milder disease at baseline or they were more carefully followed
throughout the course.48 Hence, it is important to have proper
counseling, close monitoring, and adequate management during
pregnancy.Management during pregnancy
Blood transfusion was used once during pregnancy in 4 cases of
the Bedouin registry, and all women required blood transfusions
at delivery, despite being transfusion independent before
pregnancy.50 Another previously asymptomatic 32-year-old
female with CDA I suffered from severe anemia in her third
trimester, and required RBC transfusions for 6 consecutive
months, along with a successful IFN-a treatment for 4 months
before her Hb stabilized again.51
Careful follow up of total Hb levels at least once a month
during pregnancy was significantly associated with better fetal
outcomes (SGA rate) in CDA I pregnancies. Expert recommen-
dations are to transfuse the mothers once symptomatic or based
onHb levels if below 8g/dL or in the case of a rapid fall by 2g/dL,
to perform monthly ultrasonography follow-ups of fetal growth
starting from week 20 of gestational age, and close fetal
monitoring in the third trimester.48,50 High dose folic acid
supplementation is recommended (800–1000mg daily), and if
significant iron overload is suspected, endocrine and cardiac
status should be checked. The high platelet counts associatedwith
splenectomy may justify the use of low doses of aspirin to
minimize thromboembolic risk.47
On the other hand, regarding iron overload management, we
suggest applying the guidelines for iron chelation of thalassemic
patients which has been used with successful results in CDA cases
of iron overload.36
Box 2: Summary of the Practical Recommendations
for CDA.Monitor Hb level and transfuse if symptomatic or fetal
growth distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Acetyl salicylic acid 80 to 100 mg once daily during
pregnancy
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia6
Thalassemia
Thalassemia patients can be classified as transfusion depen-
dent thalassemia (TDT) or non-transfusion dependent thalasse-
mia (NTDT) based on their blood transfusion requirement.
Patients with TDT commonly present with severe anemia in their
early childhood and they require regular lifelong blood trans-
fusions for survival. Patients with b-thalassaemia major and
severe forms of hemoglobin E/b-thalassaemia are classified as
having TDT.52 Patients with NTDT usually present with mild/
moderate anemia during their late childhood or even in
adulthood and may necessitates intermittent or occasional
transfusions in certain clinical settings and for the prevention
or management of certain disease manifestations. Patients with
b-thalassaemia intermedia, hemoglobin H disease, and mild-to-
moderate forms of hemoglobin E/b-thalassaemia often fall under
the classification of NTDT.53 Key milestones have been achieved
in optimizing the management of thalassemia with transfusion
and iron chelation therapy, in addition to new non-invasive
methods for early detection of iron overload, which have
prolonged the survival of patients and improved their overall
quality of life. As a result, pregnancy, which was almost
impossible, in recent decades has proven to be not only possible
but also safe, with remarkable improvements in maternal and
fetal survival.Transfusion dependent thalassemia (TDT)
Pregnancy-specific complications
Although conception is possible in TDT patients who are well-
transfused and well-chelated and undergo normal puberty and
menstrual function, the majority of patients aged >25 years of
age are sub-fertile mainly due to hypogonadotropic hypogonad-
ism as a consequence of transfusional hemosiderosis and
endocrinopathies.54 To note, endocrinopathies including diabe-
tes mellitus, hypothyroidism, hypoparathyroidism, and hypo-
gonadism are common in TDT especially in patients with
elevated serum ferritin levels >2500mg/l or spelenctomized.55
Women who fail to achieve a spontaneous pregnancy might
benefit from assisted reproductive techniques (ART). A planned
pregnancy is essential both in spontaneous, or ART conceptions
since pregnancies in TDT-affected women are high risk for both
the mother and the baby.56Management during pregnancy
In patients with TDT, certain precautions before and during
pregnancy should be considered. Patients are subject to cardiac
impairment, liver dysfunction, and chronic viral infections. A
multidisciplinary assessment preconception is essential to support
a good pregnancy outcome. The evaluation of cardiac function is
important given that cardiac complications remain the leading
cause of death in transfusion-dependent patients.57 During
pregnancy, the cardiac load is increased by at least 25% to
30% as a result of an increase in both heart rate and stroke
volume. Cardiac stress, in addition to an increased iron load, can
lead to cardiac failure. It is therefore essential for all TDT patients
to undergo a pre-conceptional, complete cardiological evaluation
including echocardiography testing for left ventricular ejection
fraction and other functional parameters, and a 24-hour Holter
monitoring to check for any rhythm disorders.56 Moreover, a
pre-pregnancy cardiac T2∗ of the heart of greater than or at least
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of significant cardiac iron overload (T2∗MRI  10 ms), or those
with cardiac dysfunction, should be discouraged from planning a
pregnancy at that time pending optimization to their normal
values.58
As for liver dysfunction before pregnancy, all TDT women
should have their liver iron load assessed preferentially byMRI or
in cases of potential liver disease by liver biopsy. An abdominal
ultrasound for liver and spleen volume as well as a gallbladder
evaluation should be obtained. Thalassemia patients have an
increased risk of gallstones: in those patients with evidence of
sludge or stones, cholecystectomy should be considered before
conception.59 In terms of management of these patients, for
women who were transfusion-dependent prior to pregnancy,
regular transfusions should continue with a pre-transfusion
hemoglobin goal of ≥ 10g/dL. The use of iron chelation therapy
during pregnancy has not been addressed in clinical studies and
remains controversial. The current standard of practice is to
discontinue chelation therapy as soon as pregnancy is established.
Reproductive studies in non-iron-loaded rats and rabbits have
indicated that deferiprone (DFP) is teratogenic and embryo-
toxic.60,61 Although successful pregnancies following uninten-
tional treatment with DFP or deferasirox (DFX) have been
reported in the literature,61–63 the use of oral iron chelators is
contraindicated in pregnant women, because of the lack of
controlled data.
Women of childbearing age on oral chelators who are
planning a pregnancy should be counseled and advised to
switch to deferoxamine (DFO). However, discontinuation of
iron chelation with DFO should be recommended once a
pregnancy has been achieved.34 Nevertheless, it may be
reasonable to consider restarting chelation therapy with DFO
during the third trimester in patients in patients with severe iron
overload in the heart and liver, when the potential benefits
outweigh the potential risks to the fetus.34,64 After delivery,
DFO can be recommenced because concentrations are very
low in breast milk and because it is not absorbed when taken
orally.
Box 3: Summary of the Practical Recommendations
for TDT.Monitor Hb level and maintain the pre-transfusion Hb no
less than 9.5g/dL
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Assess cardiac status with echocardiography (preferably
every trimester) and manage accordingly
Consider DFO towards the end of the second trimester in
patients with severe iron overload in the heart and/or liver
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Splenectomized patient should be considered for acetyl
salicylic acid 80 to 100 mg once daily during pregnancy7
Non-transfusion dependent thalassemia (NTDT)
Pregnancy-specific complications
Pregnancy has been reported to be safe in most women with
NTDT under multidisciplinary management. Pregnancies in this
patient population have mostly been achieved without routine
assisted reproductive technologies.63,65 The physiologic anemia
of pregnancy becomes exaggerated in NTDT patients, and the
increased oxygen demand by the fetus makes blood transfusion a
tempting option. The major factors of pregnancy-related
adversities in NTDT females are iron overload and increased
thrombotic risk. In NTDT, where the levels of hepcidin are
abnormally low, excess iron is absorbed into the system leading
to preferential portal and hepatocyte iron loading and free iron in
the bloodstream resulting in organ damage and pregnancy
complications.66 Venous thromboembolism is the most serious
complication seen in this patient population; especially in women
with additional prothrombotic risk factors such as splenectomy,
age and low Hb level.67,68 An incidence greater than 30% of
venous thromboembolic events has been reported in NTDT
patients, reflecting a hypercoagulable state that is driven by
several mechanisms including endothelial damage secondary to
the iron-mediated free radical formation.69 Other studies,
however, show that pregnancy in NTDT patients was not shown
to increase the risk of thromboembolic complications compared
to non-pregnant NTDT women.68Management during pregnancy
Blood transfusion therapy is a common consideration in
pregnant NTDT women due to the worsening of anemia during
gestation. There are no clear cutoffs on when to transfuse, and the
only determining factor is the clinical status of the patient. Data
from non-thalassemia cohorts suggest that hemoglobin levels ≥
10g/dL during gestation are recommended for optimal fetal
growth and development.12 However, an Italian case series
showed that targeting a 10g/dL cutoff level proved beneficial only
in 78% of the pregnant NTDT patients.63 As such, the
introduction of blood transfusions for pregnant patients with
NTDT should rely on hemoglobin level, maternal general health,
and cardiac status along with fetal growth status. Furthermore,
pregnant women with NTDT who were previously never- or
minimally-transfused, should be considered at high risk of
alloimmunization if blood transfusions are to be administered
during pregnancy.70 If blood transfusion is necessary, then an
extended genotype and antibody screening should be performed
at first. A recent study describes 4 patients who developed
alloimmune hemolytic anemia after transfusion that necessitated
postpartum splenectomy in two of them.71 Hence, splenectomy
should be considered for NTDT patients with hypersplenism or
splenomegaly before conception or postpartum.
Thalassemia, in particular for the patients who are non-
transfused and splenectomized, is a hypercoagulable state that
involves interactions of disrupted thalassemic red blood cell
membrane surfaces, platelets, and endothelium.72,73 Therefore,
pregnant women with NTDT should receive a prophylactic dose
of low-molecular-weight heparin (LMWH) peripartum.70
Patients with a history of recurrent abortions or who are at
increased risk of thromboembolic events may be prescribed
LMWH throughout pregnancy. Splenectomized patients should
also be considered for acetyl salicylic acid (ASA) therapy if they
are not prescribed LMWH.70
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for NTDT.Monitor Hb level and transfuse if symptomatic or fetal
growth distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Assess cardiac status with echocardiography and manage
accordingly
Discontinue use of hydroxyurea
Prophylactic dose of LMWH should be considered in
peripartum period
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Splenectomized patient should be considered for acetyl
salicylic acid 80 to 100 mg once daily during pregnancy
unless prophylactic use of LMWH is prescribed
Sickle cell disease
Sickle cell disease (SCD) is a worldwide distributed hereditary
red cell disorder that affects approximately 100,000 individuals
in the United States and between 20,000 and 25,000 individuals
in Europe, mainly through immigrants from endemic areas such
as Sub-Saharan Africa.74–76 Estimates of the number of affected
new-born in 2010 are of approximately 312,302 subjects, 75.5%
of which were born in Africa.77 SCD is caused by a point
mutation in the b-globin gene resulting in the synthesis of
pathological hemoglobin S (HbS) with subsequent generation of
rigid, dense and dehydrated red cells.78–80 The main clinical
manifestations of SCD are chronic hemolytic anemia and acute
vaso-occlusive crisis, leading to an impaired blood flow with
ischemic/reperfusion injury.78,81–83 A complex perturbation of
hemostasis has been reported in SCD both under a steady state
and during acute events. Clinical manifestations of the pro-
thrombotic state of SCD patients include venous thromboembo-
lism, in situ thrombosis and stroke, (most in splenectomized
patients or with functional asplenia).78
Hydroxyurea or hydroxycarbamide (HU) is still today the key
therapeutic tool for SCD that is approved by both the Food and
Drug Administration (FDA) and European Medicines Agency
(EMA). In addition, different blood transfusion regimens, such as
transfusion on demand or chronic transfusion, automatized/
manual red cell exchange, may be used in the clinical
management of both acute and chronic sickle cell-related
complications. The main objective of the transfusion approach
is to rapidly reduce/maintain low percentage of HbS in the
peripheral circulation. In SCD, transfusion related iron-overload
organ damage is generally underestimated, mainly due to
difficulties in collecting information on patient transfusion
history. Indeed, an adult patient with SCD might be treated
with red cell transfusion for acute vaso-occlusive crises (VOCs)
or even placed on chronic transfusion program for the
management of chronic sickle cell pain although the benefit is
controversial.848
Pregnancy-specific complications
In the last decade, progress in the clinical management of SCD
has improved the survival of patients with SCD.85 Thus, a larger
number of SCD women have reached the reproductive age,
thereby requiring a multidisciplinary care team to support their
pregnancy.4,86–89 Indeed, poor outcomes for pregnancy in SCD
women with high maternal and fetal mortality and morbidity
have been reported.88,90 Three main categories of complications
have been identified: (i) the severe clinical manifestations related
to SCD (ie, recurrent acute VOC, acute chest syndrome); (ii) the
medical complication of pregnancy (ie, urinary infection,
pyelonephritis); and (iii) the obstetrical complications (pre-
eclampsia, intrauterine growth retardation-IUGR).87–89,91 In
SCD, prediction of the course of pregnancy is often very difficult
to establish due to the variability in the severity of SCD
phenotype. Thus, a proper assessment of chronic disease
complications in a multidisciplinary setting (ie, screening
pulmonary hypertension, iron overload, hypertension and/or
proteinuria, for nephropathy and/or hepatic dysfunction,
proliferative retinopathy) should be made and the presence of
alloantibodies should be carried out ideally prior to conception.92
Due to the recurrent blood transfusions, SCD patients are at
higher risk of alloimmunization.93 Almost half of the patients will
have alloantibodies which will increase the risk of hemolytic
disease in the fetus. Hence, any SCD women with high frequency
of transfusions should be tested for RBC alloantibodies and
managed accordingly.94 This will allow to differentiate women
with SCD with a mild phenotype from those with a more severe
phenotype (identify chronic organ damages), who require a more
intense therapeutic approach and rigorous follow-up.
Management during pregnancy
SCD women should have a strict follow up at the reference
center as well as at the obstetric-sickle clinics at least every 2 to 3
weeks and preferably weekly starting from 32 weeks of gestation.
During pregnancy, follow-up of chronic disease complications if
they exist as well as obstetric complications are the basis of care.
Careful monitoring of fetal growth by serial ultrasonography
combined with determination of arterial impedance (umbilical
arterial Doppler) is recommended for the risk of intra-uterine
growth restriction (IUGR). Hydroxyurea and iron chelation
therapy should be discontinued at least 3 months before
conception or as soon as the pregnancy test is positive if
conception has inadvertently occurred while on the medication.
Regular monitoring should include an urinalysis and blood
pressure measurement to identify and treat the urinary tract
infections or pre-eclampsia as early as possible.87–89,91 Although
there is no evidence about the role of ASA therapy in pregnant
SCD women, it has been shown that ASA can reduce the risk of
pre-eclampsia in women with high risk pregnancies.95 Thus, 80
to 100mg daily dose of oral ASA may be appropriate after week
12 of gestation, unless major contra-indications are present.
However, no evidence-based consensus on this issue has been
published. Although the risk of venous thromboembolism (VTE)
in SCD women increases fivefold during pregnancy, and studies
of placental pathology have indicated the presence of ischemic-
reperfusion damage and local thrombosis,96 there is no consensus
on the use of anticoagulant treatment. However, SCD women
with a history of VTE, at risk for the occurrence of VTE or who
are hospitalized for acute medical complications should receive
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for a period of time after delivery.4,89,97
The use of prophylactic RBC transfusion during pregnancy to
reduce sickle cell-related clinical complications and ameliorate
maternal/fetal outcomes is supported by a randomized study.98 A
recent meta-analysis demonstrated a positive association between
prophylactic transfusion and reduction in maternal mortality and
neonatal complications in SCD.86 A further randomized
controlled study comparing prophylactic transfusions with
standard of care is currently under way: https://clinicaltrials.
gov/ct2/show/NCT03975894. In addition, a few retrospective
studies have also shown the beneficial effects of prophylactic
erythrocytapheresis on maternal/fetal outcomes in SCD wom-
en.99–101 Data on prophylactic transfusion during pregnancy is
controversial. As pregnancy outcome is not clearly correlated
with routinely prophylactic transfusion, it is not recommended in
SCD women with an uncomplicated pregnancy. A recent dual
center retrospective cross sectional study on pregnancies in SCD
women with history of severe sickle cell-related clinical
manifestations treated with early prophylactic erythrocytaphe-
resis (10.7+/ 5.2 weeks of gestation) and anticoagulation
prophylaxis with enoxaparin showed improvement of maternal
outcomes and newborn weights.96 A prophylactic transfusion
regimen should be initiated as early as possible in women with
severe sickle cell-related clinical manifestations or pre-eclampsia/
eclampsia.102
The timing and mode of delivery should be according to
obstetric indications and/or the severity of SCD clinical
manifestations. SCD women with a mild phenotype might go
to spontaneous labor and normal vaginal delivery. Oxygen
support should be provided during labor (to maintain oxygen
saturation ≥ 94%), the patient should be kept warm, and
hydration should be adequate to prevent life-threatening
complication such as ACS.87,103 In the case of cesarean delivery,
preoperative transfusion therapy to reach a hemoglobin level of
10g/dL and an HbS <40% is strongly recommended. Throm-
boprophylaxis with LMWH is recommended in these patients
pre- and post a cesarean section.
Box 5: Summary of the Practical Recommendations
for SCD.Monitor Hb level and transfuse if symptomatic or fetal
growth distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Discontinue use of hydroxyurea
Regular urinalysis and blood pressuremeasurement at every
clinic visit at least monthly
During Labor: Oxygen support (to maintain oxygen
saturation ≥ 94%), the patient should be kept warm, and
proper intravenous hydration. HbS <40% is strongly
recommended in case of cesarean section
Acetyl salicylic acid 80 to 100 mg daily during pregnancy
after week 12 of gestational age9
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Peripartum thromboprophylaxis with LMWH is recom-
mended in case of cesarean section or vaginal delivery
Enzyme deficiencies
Pyruvate kinase deficiency (PKD) is the most frequent enzyme
abnormality of the glycolytic pathway (estimated prevalence is 1–
5 per 100,000 in the Caucasian population; higher frequencies in
the Pennsylvania Amish and the Gypsy communities from a
founder effect).104 Clinical manifestations reflect the symptoms
and complications of lifelong chronic hemolysis, including
anemia, jaundice, gallstones, splenomegaly, and iron overload.
The severity of symptoms is highly variable, ranging from fully
compensated hemolysis to life-threatening anemia requiring
neonatal exchange transfusions and/or later regular transfusions.
PKD is inherited in an autosomal recessive fashion and is caused
by homozygous or compound heterozygous variants in the PKLR
gene located on chromosome 1q21. To date, more than 300
mutations have been reported, and genotype-phenotype correla-
tion studies have shown that patients with severe hemolytic
anemia more commonly have deleterious mutations or missense
pathogenic variants that affect the active site or stability of the PK
protein.
Current management of PKD is based on red cell trans-
fusions, chelation, and splenectomy. More than 80% of
individuals with PKD have been transfused at least once in
their lifetime. Splenectomy,which is performed in about 50%of
patients with PKD, ameliorates anemia in the majority of
patients (median rise in hemoglobin of 1.6g/dL) and decreases
the transfusion burden. However, it carries the risk of post-
splenectomy sepsis due to encapsulated organisms, thus is
typically delayed until 5 years of age if possible. Splenectomy
also carries the risk of thrombosis (11% in the PKD series, all
splenectomized). Moreover, about 10% to 15% of splenec-
tomized cases still remain transfusion-dependent, and surgery
does not abolish hemolysis, jaundice and the risk of gallstones.
Finally, iron overload occurs in about half of PKD patients, and
correlates with disease severity and transfusion requirement,
but is also observed in milder cases. Therefore, timing and risk
of post-splenectomy sepsis and thrombosis must be weighed
against the risks of iron loading in patients treated with regular
transfusions.104
Regarding the other enzyme defects, there is no specific
information available. For this reason, we recommend the
general approaches suggested for PK deficiency.Pregnancy-specific complications
Data on pregnancy in women with PKD are scarce, mainly
based on case reports105,106 and the recently published large
series on the PKD natural history.105–107 Older series report that
pregnancy had been associated with a good maternal and fetal
outcome. However, more accurate data come from the 79 post-
menarchal females among the 254 patients enrolled in the PKD
Natural History study, of whom 39 (about 50%) had at least one
pregnancy (total of 115) prior to enrollment. Pregnancy
outcomes included 82 live births, of whom 70 full term and
12 preterm. Therefore, preterm births occur in about 10%, and
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with rates not different from the healthy female population.
Pregnancy is recognized as a hemolytic trigger,104–106,108,109
requiring transfusion support, with frequencies comparable to
that of infectious episodes. The great majority of females enrolled
in the PKD Natural History study have been transfused during
pregnancy. In fact, 75% were transfused during pregnancy and
38% after delivery, as compared with only 6% prior to
pregnancy.
Management during pregnancy
The recommendations for pregnancy management include
transfusions to support a higher hemoglobin nadir in the mother
and close monitoring of fetal growth by a multidisciplinary
approach (hematologist and expert obstetrician).110 However,
there are no specific recommendations for having a hemoglobin
threshold for transfusion, other than mother wellness and fetal
growth. Some obstetricians recommend monthly ultrasounds to
assess fetal growth after 20 weeks and biophysical profiles by at
least 32 weeks.106 Folic acid supplementation should be given
generously prior to conception and during pregnancy (800–
1000mg daily). Iron supplementation is not recommended, unless
there is a documentation of true iron deficiency by laboratory
iron testing. Prior to conception, screening for hepatitis B and C
and HIV in previously transfused PKD patients, in addition to an
echocardiogram to evaluate cardiac function, and correction of
iron overload are also advisable.
Finally, fertility in women with PKD appears to be like that of
the general population, and the majority of pregnancies (98%)
did not require female assisted reproduction. Of note, 94% of
patients reached a normal puberty, and only a small fraction of
them had a delayed one and/or required hormone administration.
Box 6: Summary of the Practical Recommendations
for Enzyme Deficiency.Monitor Hb level and transfuse if symptomatic or fetal
distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Acetyl salicylic acid 80 to 100 mg once daily during
pregnancy
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Red cell membrane disorders
Red cell membrane disorders encompass a vast group of
hemolytic anemias that greatly differ by clinical, morphological,
laboratory and molecular features. The hereditary forms can be
broadly classified into 2 types: (1) erythrocyte disorders caused by
altered membrane structural organization, such as hereditary
spherocytosis (HS), and (2) erythrocyte disorders caused by
altered membrane transport function, such as dehydrated
hereditary stomatocytosis (DHS).111 Red cell membrane10disorders can be associated with a wide range of genetical
alterations depending on their subtype. While some can have
recessive inheritance pattern such as mutation in SPTA1 gene
seen in HS, others are dominant like SPTB, SLC4A1, ANK1
genes.112 The primary clinical manifestations are hemolytic
anemia, jaundice, reticulocytosis, splenomegaly, and cholelithia-
sis.111,113 HS is the most common non-immune hemolytic anemia
with a prevalence of 1:2000–5000 in the Caucasian popula-
tion.113 HS can present a broad spectrum of clinical severity,
ranging from asymptomatic to severe transfusion-dependent
forms, even within the same family. The intra-familial heteroge-
neity can be ascribed to the co-inheritance of genetic variants
involved in erythrocyte defects themselves or in other disor-
ders.114 Dehydrated hereditary stomatocytosis (DHS) is the most
common form of hereditary stomatocytosis. Patients have a well-
compensated hemolytic anemia, with a high reticulocyte count, a
tendency to macrocytosis and mild jaundice. Secondary hemo-
chromatosis is the most harmful complication in DHS patients,
particularly in those with mutations in the PIEZO1 gene.115–117
The first-line treatment is based on supportive care. For
example, HS neonatal patients may need phototherapy or
exsanguinous-transfusions.118 Some newborns may necessitate
transfusions. In these patients, recombinant erythropoietin can
reduce transfusion requirements.119 Transfusions may be
administered as needed in adulthood, mostly during aplastic
or hemolytic crises.113 Splenectomy could be suggested in several
cases of red cell membrane defects, resulting in an increased life
span of erythrocytes. Currently, total splenectomy is recom-
mended in adult patients with severe forms of HS; otherwise, in
patients with mild or moderate anemia, splenectomy is so far not
recommended.13 Conversely, splenectomy is contraindicated in
DHS due to the increased risk of thromboembolic complications,
probably related to the increased number of circulating
stomatocytes.113,115Pregnancy-specific complications
There is very minimal data in the literature on pregnancy
complicated by red blood membrane defects. However, some
reports describe the effect of pregnancy on the course of
HS.120,121 In most investigated women, pregnancy per se did not
cause any problems. Nevertheless, an increase in spherocytes,
osmotic fragility, and auto-hemolysis during pregnancy were
reported.120 Approximately 40% of patients during pregnancy
developed new or worsening anemia, with one third as a
consequence of a hemolytic crisis. In a few cases, pregnancy led to
megaloblastic anemia secondary to folate deficiency. In splenec-
tomized patients the incidence of complaints was reduced.121
Anemia requiring transfusion during pregnancy occurred in
30.7% of the births121
Regarding the fetal outcome, fetal losses in women with HS
during the first trimester have been reported.121 Several cases of
nonimmune hydrops fetalis associated with recessive HS have
been also described. In particular, these cases are due to near-
complete or complete a-spectrin deficiency, caused by homozy-
gous or compound heterozygous nonsense variants in the SPTA1
gene that can cause fatal hydrops fetalis in the third trimester of
pregnancy or perinatally.122,123 Similarly, recurrent prenatal
ascites and hydrops secondary to DHS have been also
described.124–127 A recent study showed perinatal edema
secondary to DHS in 17% of the cases, mostly associated with
PIEZO1 mutations.126 The main forms of perinatal edema
secondary to DHS are hydrops, pleural effusion, and ascites.126
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variable even between patients carrying identical PIEZO1
mutations. For example, there are several cases of patients with
the R2456H mutation in PIEZO1 without perinatal edema;128
while incompletely penetrant perinatal edema was noted in two
other families carrying the same mutation.129Management during pregnancy
In patients with increased folate demands, such as pregnant
women, folic acid supplementation is recommended.113 In
particular, 800 to 1000mg of folic acid daily is necessary for
pregnant womenwith chronic hemolytic anemias such asEPB42-
related HS.130 Monitoring for the exacerbation of anemia with a
CBC and reticulocyte count is recommended in pregnant women
with HS, as both hemolytic crisis and persistent anemia have been
reported during pregnancy, especially in women who have not
undergone splenectomy.121 All the patients must follow the
regular follow up for pregnant women with repeated ultrasound
to monitor the fetus growth.
The cases of severe fetal anemia are generally managed with in
utero erythrocyte transfusions,123,125 while the cases of severe
perinatal edema may require in utero punctures or after-birth
fluid drainage to avoid severe complications and fatal out-
comes.126,131 Symptomatic treatment of the perinatal edema is
still being debated to prevent pulmonary hypoplasia or Prune
Belly syndrome since spontaneous resolution may occur in the
first months of life. However, in published cases, ascites and
amniotic fluid were drained as a precaution.129
Box 7: Summary of the Practical Recommendations
for Red Cell Membrane Disorders.Monitor Hb level and transfuse if symptomatic or fetal
growth distress (consider transfusion if Hb < 8 to 10g/dL)
Monthly utero-placental doppler ultrasound starting week
20 of gestational age to monitor growth restriction, fetal
distress or hydrops fetalis
Genetic counseling on risk of fetal attaint with red cell
membrane disorder
Evaluate iron overload status (Ferritin, Transferrin Satura-
tion) and ensure adequate management of iron overload
Acetyl salicylic acid 80 to 100 mg once daily during
pregnancy
Regular folic acid supplementation of 800–1000mg daily to
prevent superimposed megaloblastic anemia
Conclusions
In conclusion, routine obstetrical care for all patients with rare
anemias during pregnancy before and after delivery is strongly
recommended. Proper counseling prior to pregnancy should take
into account a multidisciplinary global assessment of the disease
and individualization of each patient. The importance of
collaboration among different specialists taking care of the
pregnant patient should be emphasized. An international registry
tracking all pregnancies in women with rare anemias reported in
the literature is needed and could be of use in outlining11pathophysiological trends and management recommendations
unique to this special population.References
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